
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New York-Chronic persistent acne in adult women is a common problem that often has some underlying hormonal influence, said Diane S. Berson, M.D., at the American Academy of Dermatology's Academy '04 here.






